Cargando…

Reliability of dopamine transporter PET measurements with [(18)F]FE-PE2I in patients with Parkinson’s disease

BACKGROUND: Reliable quantification of dopamine transporter (DAT), a biomarker for Parkinson’s disease (PD), is essential for diagnostic purposes as well as for evaluation of potential disease-modifying treatment. Due to degeneration of dopaminergic neurons and thus lower expected radioligand bindin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kerstens, Vera S., Fazio, Patrik, Sundgren, Mathias, Matheson, Granville J., Franzén, Erika, Halldin, Christer, Cervenka, Simon, Svenningsson, Per, Varrone, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427674/ https://www.ncbi.nlm.nih.gov/pubmed/32797307 http://dx.doi.org/10.1186/s13550-020-00676-4

Ejemplares similares

[(18)F]FE-PE2I DAT correlates with Parkinson’s disease duration, stage, and rigidity/bradykinesia scores: a PET radioligand validation study
por: Kerstens, Vera S., et al.
Publicado: (2023)

Simplified quantification of [(18)F]FE-PE2I PET in Parkinson’s disease: Discriminative power, test–retest reliability and longitudinal validity during early peak and late pseudo-equilibrium
por: Brumberg, Joachim, et al.
Publicado: (2020)

Longitudinal DAT changes measured with [(18)F]FE-PE2I PET in patients with Parkinson’s disease; a validation study
por: Kerstens, V.S., et al.
Publicado: (2023)

D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients
por: Stenkrona, Per, et al.
Publicado: (2019)

High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson’s disease cohort
por: Fazio, Patrik, et al.
Publicado: (2020)

Microsome Mediated in Vitro Metabolism: A Convenient Method for the Preparation of the PET Radioligand Metabolite [(18)F]FE-PE2I-OH for Translational Dopamine Transporter Imaging
por: Schou, Magnus, et al.
Publicado: (2023)

[(11)C]SCH23390 binding to the D(1)-dopamine receptor in the human brain—a comparison of manual and automated methods for image analysis
por: Stenkrona, Per, et al.
Publicado: (2018)

PET imaging of [(11)C]PBR28 in Parkinson’s disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding
por: Varnäs, Katarina, et al.
Publicado: (2018)

Is dopamine D1 receptor availability related to social behavior? A positron emission tomography replication study
por: Plavén-Sigray, Pontus, et al.
Publicado: (2018)

Kinfitr — an open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability
por: Tjerkaski, Jonathan, et al.
Publicado: (2020)

Assessment of simplified ratio-based approaches for quantification of PET [(11)C]PBR28 data
por: Matheson, Granville J., et al.
Publicado: (2017)

PET Imaging of VMAT2 with the Novel Radioligand [(18)F]FE-DTBZ-d4 in Nonhuman Primates: Comparison with [(11)C]DTBZ and [(18)F]FE-DTBZ
por: Nag, Sangram, et al.
Publicado: (2021)

Novel Imaging Biomarkers for Huntington’s Disease and Other Hereditary Choreas
por: Fazio, Patrik, et al.
Publicado: (2018)

Dopamine transporter imaging with [(18)F]FE-PE2I PET and [(123)I]FP-CIT SPECT—a clinical comparison
por: Jakobson Mo, Susanna, et al.
Publicado: (2018)

M7. LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS – A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY
por: Victorsson, Pauliina, et al.
Publicado: (2020)

Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis
por: Plavén-Sigray, Pontus, et al.
Publicado: (2021)

A randomized placebo-controlled PET study of ketamine´s effect on serotonin(1B) receptor binding in patients with SSRI-resistant depression
por: Tiger, Mikael, et al.
Publicado: (2020)

Sertraline treatment influences [(18)F]FE-PE2I PET imaging for Parkinsonism
por: Justesen, Thomas E. H., et al.
Publicado: (2023)

Quantification of the purinergic P2X(7) receptor with [(11)C]SMW139 improves through correction for brain-penetrating radiometabolites
por: Brumberg, Joachim, et al.
Publicado: (2022)

Clinical brain PET research must embrace multi-centre collaboration and data sharing or risk its demise
por: Matheson, Granville James, et al.
Publicado: (2019)

Test-retest reliability and convergent validity of (R)-[(11)C]PK11195 outcome measures without arterial input function
por: Plavén-Sigray, Pontus, et al.
Publicado: (2018)

Guidelines to PET measurements of the target occupancy in the brain for drug development
por: Takano, Akihiro, et al.
Publicado: (2016)

Revisiting the Logan plot to account for non-negligible blood volume in brain tissue
por: Schain, Martin, et al.
Publicado: (2017)

[(18)F]FE-PE2I PET is a feasible alternative to [(123)I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism
por: Marner, Lisbeth, et al.
Publicado: (2022)

Quantification and reliability of [(11)C]VC - 002 binding to muscarinic acetylcholine receptors in the human lung — a test-retest PET study in control subjects
por: Cselényi, Zsolt, et al.
Publicado: (2020)

We need to talk about reliability: making better use of test-retest studies for study design and interpretation
por: Matheson, Granville J.
Publicado: (2019)

Does Information from the Parkinson KinetiGraph™ (PKG) Influence the Neurologist’s Treatment Decisions?—An Observational Study in Routine Clinical Care of People with Parkinson’s Disease
por: Sundgren, Mathias, et al.
Publicado: (2021)

PET technology for drug development in psychiatry
por: Arakawa, Ryosuke, et al.
Publicado: (2020)

Multivariate analysis of PET pharmacokinetic parameters improves inferential efficiency
por: Matheson, Granville J., et al.
Publicado: (2023)

Correction: [(18)F]FE-PE2I PET is a feasible alternative to [(123)I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism
por: Marner, Lisbeth, et al.
Publicado: (2023)

Effect of DL-Methylephedrine on Dopamine Transporter Using Positron Emission Tomography With [(18)F]FE-PE2I
por: Nogami, Tsuyoshi, et al.
Publicado: (2022)

ABC transporter-dependent brain uptake of the 5-HT(1B) receptor radioligand [(11)C]AZ10419369: a comparative PET study in mouse, rat, and guinea pig
por: Tóth, Miklós, et al.
Publicado: (2014)

Decreased defluorination using the novel beta-cell imaging agent [(18)F]FE-DTBZ-d4 in pigs examined by PET
por: Jahan, Mahabuba, et al.
Publicado: (2011)

Simultaneous multifactor Bayesian analysis (SiMBA) of PET time activity curve data
por: Matheson, Granville J., et al.
Publicado: (2022)

PE and PET oligomers’ interplay with membrane bilayers
por: Järvenpää, Joni, et al.
Publicado: (2022)

Serotonin 5-HT(1A) receptor binding and self-transcendence in healthy control subjects—a replication study using Bayesian hypothesis testing
por: Griffioen, Gina, et al.
Publicado: (2018)

Changes in dopamine D2-receptor binding are associated to symptom reduction after psychotherapy in social anxiety disorder
por: Cervenka, S, et al.
Publicado: (2012)

PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [(18)F]PF-06684511
por: Arakawa, Ryosuke, et al.
Publicado: (2020)

Dual tracer tau PET imaging reveals different molecular targets for (11)C-THK5351 and (11)C-PBB3 in the Alzheimer brain
por: Chiotis, Konstantinos, et al.
Publicado: (2018)

Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline
por: Sturm, Stefan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_voa39nv4fo5fe2ec27o6h388pc